Randomized phase III study of CPT-11 versus Weekly Paclitaxel for unresectable or recurrent gastric cancer refractory to combination chemotherapy with fluoropyrimidine plus platinum.
Phase 3
- Conditions
- unresectable or recurrent gastric cancer refractory to combination chemotherapy with fluoropyrimidine plus platinum
- Registration Number
- JPRN-UMIN000001252
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 220
Inclusion Criteria
Not provided
Exclusion Criteria
1.Serious medical condition such as infection, heart disease 2.Massive pleural effusion or ascites or pericardial effusion 3.Hypersensitivity or neuropathy 4.Interstitial pneumonia 5.CNS metastasis 6.Pregnancy or breast-feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method overall survival
- Secondary Outcome Measures
Name Time Method response rate, progression free survival, toxicity, rate of subsequent chemotherapy